Tongling Jieya Biologic Technology Co., Ltd. reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was CNY 525.64 million compared to CNY 814.5 million a year ago. Revenue was CNY 525.64 million compared to CNY 814.5 million a year ago.

Net income was CNY 128.93 million compared to CNY 185.16 million a year ago. Basic earnings per share from continuing operations was CNY 1.59 compared to CNY 3.04 a year ago. Diluted earnings per share from continuing operations was CNY 1.59 compared to CNY 3.04 a year ago.